Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
17.44
0.00 (0.00%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,074 | 3,961 | 2,454 | 1,861 | 301 | 715 | |
Market Cap Growth | 102.73% | 61.41% | 31.88% | 517.29% | -57.87% | 6.05% |
Enterprise Value | 8,735 | 6,511 | 5,081 | 4,434 | 2,989 | 3,372 |
Last Close Price | 17.44 | 12.60 | 7.92 | 6.07 | 1.99 | 4.79 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 36.27 | 54.97 | - | - | - | 67.35 |
Forward PE | 17.58 | 15.04 | 11.69 | 11.92 | 2.71 | 5.65 |
PS Ratio | 1.95 | 1.31 | 0.88 | 0.78 | 0.14 | 0.34 |
PB Ratio | 168.64 | 664.26 | -55.10 | 30.35 | 1.44 | 1.86 |
P/FCF Ratio | 73.09 | 16.43 | 10.45 | 6.23 | 18.49 | 3.75 |
P/OCF Ratio | 30.25 | 11.65 | 8.32 | 5.38 | 4.63 | 2.96 |
PEG Ratio | - | 0.51 | 0.51 | 0.51 | 0.18 | 0.66 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.80 | 2.16 | 1.82 | 1.85 | 1.35 | 1.61 |
EV/EBITDA Ratio | 12.67 | 10.11 | 8.69 | 9.05 | 6.79 | 7.49 |
EV/EBIT Ratio | 17.64 | 15.48 | 14.59 | 17.03 | 14.94 | 15.57 |
EV/FCF Ratio | 105.10 | 27.00 | 21.64 | 14.84 | 183.29 | 17.67 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 23.87 | 450.96 | -58.22 | 44.87 | 13.62 | 7.52 |
Debt / EBITDA Ratio | 3.94 | 4.06 | 4.31 | 5.43 | 6.15 | 6.15 |
Debt / FCF Ratio | 33.59 | 11.15 | 11.05 | 9.21 | 174.50 | 15.13 |
Net Debt / Equity Ratio | 22.74 | 402.92 | -55.70 | 43.34 | 13.49 | 6.87 |
Net Debt / EBITDA Ratio | 3.86 | 3.73 | 4.24 | 5.42 | 6.40 | 5.86 |
Net Debt / FCF Ratio | 32.01 | 9.96 | 10.57 | 8.89 | 172.79 | 13.82 |
Asset Turnover | 0.87 | 0.84 | 0.80 | 0.66 | 0.57 | 0.53 |
Inventory Turnover | 2.92 | 3.10 | 2.98 | 2.77 | 2.79 | 2.67 |
Quick Ratio | 1.38 | 1.39 | 0.82 | 0.87 | 1.10 | 1.39 |
Current Ratio | 2.21 | 2.17 | 1.41 | 1.63 | 1.88 | 2.25 |
Return on Equity (ROE) | 613.02% | - | -881.26% | -36.06% | -85.96% | 5.45% |
Return on Assets (ROA) | 8.60% | 7.32% | 6.24% | 4.48% | 3.23% | 3.41% |
Return on Invested Capital (ROIC) | 18.64% | 16.18% | 13.69% | 9.07% | 6.61% | 4.62% |
Return on Capital Employed (ROCE) | 17.10% | 15.00% | 14.70% | 9.90% | 6.60% | 6.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.59% | 1.82% | -4.76% | -4.51% | -43.12% | 1.49% |
FCF Yield | 1.37% | 6.09% | 9.57% | 16.06% | 5.41% | 26.68% |
Buyback Yield / Dilution | -3.48% | -5.12% | -75.42% | -16.69% | 0.58% | -1.95% |
Total Shareholder Return | -3.48% | -5.12% | -75.42% | -16.69% | 0.58% | -1.95% |